CANTARGIA AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.383 SEK | -1.94% |
|
-8.15% | -8.35% |
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Calendar
2024-05-21
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.45
SEK
Average target price
12.67
SEK
Spread / Average Target
+267.15%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.35% | 57.8M | |
| -2.39% | 103B | |
| +1.87% | 95.28B | |
| +1.69% | 22.15B | |
| -15.30% | 21.02B | |
| -8.58% | 18.15B | |
| -41.01% | 16.73B | |
| -13.12% | 16.05B | |
| +4.20% | 13.68B | |
| +35.72% | 12.17B |
- Stock Market
- Equities
- CANTA Stock
- Funds and ETFs Cantargia AB
